Mundipharma

• NCT02013362

  Phase 1/2, Completed, 25 people, 17 Dec 2013

• NCT01526694

  Collaborator, Phase 2, Completed, 30 people, 6 Feb 2012

• NCT01002703

  Collaborator, Phase 1/2, Status unknown, 50 people, 27 Oct 2009

• NCT00769522

  Collaborator, Phase 3, Completed, 564 people, 9 Oct 2008

• NCT00740415

  Collaborator, Phase 2, Completed, 39 people, 25 Aug 2008

• Oxidative balance-related metabolite signature and incident cardiovascular disease and type 2 diabetes within the PREDIMED trial

  Fees or honoraria, 2 Sept 2026

• Prediabetes: diagnostic aspects, clinical features, and emerging therapeutic opportunities, with a focus on Vitamin D

  Consulting or advice, Fees or honoraria, Board or leadership role, 27 Aug 2026

• A High-Fiber, Plant-Based Diet in Myeloma Precursor Disorders: Results from the NUTRIVENTION Clinical Trial and Preclinical Vk*MYC Model

  Fees or honoraria, Grants or research support, 1 Apr 2026

• More than Glucose Elimination: Additional Benefits of SGLT2 Inhibitors in Glomerular Diseases

  Consulting or advice, Fees or honoraria, Grants or research support, 15 Feb 2026

• Immunofitness in the elderly: The role of vaccination in promoting healthy aging

  Consulting or advice, Board or leadership role, 10 Feb 2026

• Tirzepatide for Older Adults with Type 2 Diabetes and Without Obesity: A Post Hoc Analysis of the SURPASS Clinical Trials

  Consulting or advice, 28 Feb 2025

• Pharmacological Treatment of Obesity in Older Adults

  Consulting or advice, Fees or honoraria, Grants or research support, 8 Nov 2024

• Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

  Fees or honoraria, 10 Oct 2022

• Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors

  Fees or honoraria, Grants or research support, 24 Nov 2021

• Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

  Fees or honoraria, 6 Aug 2021

• Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis

  Fees or honoraria, 1 Feb 2021

Sources: pubmed.ncbi.nlm.nih.gov

• Tirzepatide Prevents Palmitate-Induced Apoptosis, Autophagy, and Senescence in Human Cardiac Progenitor Cells

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025